Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2005-02-09
2009-10-20
Helms, Larry R (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S193100, C424S196110, C424S204100, C424S207100, C424S208100
Reexamination Certificate
active
07604804
ABSTRACT:
The present invention relates to multivalent HIV inhibitors that bind to multiple sites on a trimeric gp120 complex thereby blocking the CD4 binding site on the trimeric gp120 complex and inhibiting the attachment and entry of HIV through gp120-CD4 interactions.
REFERENCES:
patent: 6139843 (2000-10-01), Rubinstein et al.
patent: 0 891 982 (1999-01-01), None
patent: 0 719 281 (1999-08-01), None
Shinya et al. In vivo delivery of therapeutic proteins by genetically-modified cells: comparison of organoids and human serum albumin alginate-coated beads 1999. Biomedical and Pharmacotherapy vol. 53, pp. 471-483.
BM[PEO]2(1,8-bis-Maleimidodiethyleneglycol) [online]. Pierce Biotechnology, Inc, 2002 [retrieved on Nov. 16, 2005]. Retrieved from the Internet: <URL: https://www.piercenet.com/products/browse.cfm?fldID=02030209>.
Lalezari et al. A Controlled Phase II trial assessing three doses of enfuvirtide in combination with abacavir . . . 2003. Antiviral Therapy vol. 8 No. 4, pp. 279-287.
Wu et al. Dimeric association and segmental variability in the structure of human CD4. Nature May 29, 1997, vol. 387, p. 527-530.
McInerney et al. Mutation-Directed Chemical Cross-Linking of Human Immunodeficiency Virus Type 1 gp41 Oligomers. Journal of Virology, Feb. 1998, vol. 72, No. 2, pp. 1523-1533.
Green et al. Quantitative evaluation of the lengths of homobifunctional protein cross-linking reagents used as molecular rulers. Protein Science 2001, vol. 10, pp. 1293-1304.
Tsunehiro et al. Enzyme coupled immunoassay of insulin using a novel coupling reagent. Journal of Biochemistry 1976. vol. 79, pp. 233-236.
Richman, D.D., (2001) HIV chemotherapy.Nature 410, 995-1001.
Chan, D.C., et al., (1998) HIV entry and its inhibition.Cell 93, 681-684.
Kwong, P.D., et al., (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.Nature 393, 648-659.
Wyatt, R., et al., (1998) The antigenic structure of the HIV gp120 envelope glycoprotein.Nature 393, 705-711.
Smith, D.H., et al., (1987) Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.Science 238, 1704-1707.
Deen, K.C., et al., (1988) A soluble form of CD4 (T4) protein inhibits AIDS virus infection.Nature 331, 82-84.
Traunecker, A., et al., (1988) Soluble CD4 molecules neutralize human immunodeficiency virus type 1.Nature 331, 84-86.
Burton, D.R., et al., (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.Science 266, 1024-1027.
Saphire, E.O., et al., (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.Science 293, 1155-1159.
Martin, L., et al., (2000) Engineering novel bioactive mini-proteins on natural scaffolds.Tetrahedron 56, 9451-9460.
Vita, C., et al., (1999) Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein.Proc. Natl. Acad. Sci. USA 96, 13091-13096.
Martin, L., et al., (2003) Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes.Nat. Biotechnol. 21, 71-76.
Sanders, R.W., et al., (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.J. Virol. 76, 8875-8889.
Schulke, N., et al., (2002) Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.J. Virol. 76, 7760-7776.
Salzwedel, K., et al., (2000) Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.Proc. Natl. Acad. Sci. U S A 97, 12794-12799.
Kwong, P.D., et al., (2000) Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.J. Virol. 74, 1961-1972.
Staropoli, I., et al., (2000) Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate.J. Biol. Chem. 275, 35137-35145.
Zhu, P., et al., (2003) Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.Proc. Natl. Acad. Sci. USA 100, 15812-15817.
Mammen, M., et al., (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors.Angew. Chem. Int. Ed. 37, 2754-2794.
Kitov, P.I., et al., (2003) Optimization of tether length in nonglycosidically linked bivalent ligands that target sites 2 and 1 of a Shiga-like toxin.J. Am. Chem. Soc. 125, 3284-3294.
Dekker, F.J., et al., (2002) Replacement of the intervening amino acid sequence of a Syk-binding diphosphopeptide by a nonpeptide spacer with preservation of high affinity.Chembiochem 3, 238-242.
Kitov, P.I., et al., (2000) Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands.Nature 403, 669-672.
Fan, E., et al., (2000) High-affinity pentavalent ligands ofE. coliheat-labile enterotoxin by modular structure-based design.J. Am. Chem. Soc. 122, 2663-2664.
Kiessling, L.L., et al., (2000) Synthetic multivalent ligands in the exploration of cell-surface interactions.Curr. Opin. Chem. Biol. 4, 696-703.
Wang, L.X., et al., (2003) Carbohydrate-centered maleimide cluster as new types of templates for multivalent peptide assembling: Synthesis of multivalent HIV-1 gp41 peptides.Bioorg. Med. Chem. 11, 129-136.
Willey, R.L., et al., (1988) In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.J. Virol. 62, 139-147.
Wu, Z., et al., (2003) From pro defensins to defensins: synthesis and characterization of human neutrophil pro alpha-defensin-1 and its mature domain.J. Pept. Res. 62, 53-62.
Li, et al., (2004) Synthetic Bivalent CD4-Mimetic Miniproteins Show Enhanced Anti-HIV Activity over the Monovalent Miniprotein,Bioconjugate Chem.15, 783-789.
Li Hengguang
Wang Lai-Xi
Fuierer Marianne
Helms Larry R
Humphrey Louise
Moore & Van Allen PLLC
University of Maryland Biotechnology Institute
LandOfFree
Enhancing anti-HIV efficiency through multivalent inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancing anti-HIV efficiency through multivalent inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancing anti-HIV efficiency through multivalent inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4059831